IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. boosted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 12.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 18,327 shares of the company’s stock after buying an additional 2,078 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in IDEAYA Biosciences were worth $471,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IDYA. R Squared Ltd purchased a new stake in IDEAYA Biosciences in the fourth quarter valued at approximately $35,000. KBC Group NV grew its stake in shares of IDEAYA Biosciences by 84.6% during the 4th quarter. KBC Group NV now owns 4,197 shares of the company’s stock valued at $108,000 after buying an additional 1,923 shares during the period. SG Americas Securities LLC increased its holdings in shares of IDEAYA Biosciences by 444.2% during the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company’s stock worth $475,000 after buying an additional 15,089 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of IDEAYA Biosciences by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company’s stock worth $2,527,000 after buying an additional 12,029 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in IDEAYA Biosciences by 9.8% in the third quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company’s stock valued at $61,645,000 after acquiring an additional 172,838 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on IDYA. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Monday, January 13th. Wedbush restated an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Leerink Partners downgraded shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Leerink Partnrs downgraded shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $53.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEAYA Biosciences has an average rating of “Moderate Buy” and an average price target of $53.67.

IDEAYA Biosciences Stock Performance

Shares of IDYA opened at $24.35 on Monday. IDEAYA Biosciences, Inc. has a one year low of $22.10 and a one year high of $47.74. The stock has a 50-day moving average price of $25.23 and a 200 day moving average price of $31.22. The company has a market capitalization of $2.10 billion, a P/E ratio of -10.45 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Monday, November 4th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same period in the previous year, the firm earned ($0.46) EPS. As a group, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.